cardiovascular

heart

Biotech

Merck & Co. pens $200M upfront deal for Hengrui med

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

James Waldron Mar 25, 2025 9:10am

Harvard University School of Engineering and Applied Sciences

Roche to house its CVRM research work at new Boston hub

Mar 7, 2025 9:40am

image of a heart with a technology background

Keros ends hypertension trial over fluid buildups around heart

Jan 15, 2025 8:25am

photo of the wind blowing a tree into a 90-degree angle toward the left

Cash-strapped Windtree seeks biotechs with FDA-approved products

Jan 9, 2025 4:44am

heart

Keros halts 2 arms of hypertension trial over fluid near heart

Dec 12, 2024 6:30am

photo of the wind blowing a tree into a 90-degree angle toward the left

Windtree's shock med raises blood pressure in latest phase 2 win

Sep 25, 2024 9:59am